Loading quotes...
Forecast
| Buy |
0 |
| Hold |
1 |
| Sell |
0 |
Discussions in the community
There is no discussion about this asset yet.
Start discussionNews Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Financials
| (EUR) | September 2025 | YoY |
|---|---|---|
| Revenue | 332.33k | - |
| Gross profit | 315.29k | - |
| Net profit | -7.65m | - |
| EBITDA | -6.86m | - |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €1.44m |
Number of shares | 53.29m |
52-week high/low | €1.28 - €0.0245 |
| Dividends | No |
Beta | 3.01 |
P/E ratio | -0.14 |
PEG ratio | 0.00 |
P/B ratio | -0.31 |
P/S ratio | 6.82 |
Company profile
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.
| Name | ITERUM THERAPEUT. EO-,01 Aktie |
| CEO | Corey N. Fishman |
| Headquarters | Dublin,
Ireland |
| Website | |
| Sector | Health Care |
| Industry | Biotechnology |
| IPO | 25/05/2018 |
| Employees | 9 |
Ticker symbols
| Exchange | Symbol |
|---|---|
NASDAQ | ITRM |
